View Older Stories View More Recent Stories

May 16, 2022 07:30AM Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors
May 2, 2022 08:32AM Gilead Sciences (GILD) and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
May 2, 2022 08:30AM Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
Apr 26, 2022 06:13PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 25, 2022 02:29PM Gilead Sciences (GILD) Announces Veklury (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
Apr 25, 2022 02:29PM Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
Apr 25, 2022 05:24AM Gilead Sciences (GILD) Reports New Findings Confirming Veklury Activity in Treating COVID-19
Apr 24, 2022 06:05PM Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
Apr 19, 2022 08:07AM Gilead Sciences' (GILD) Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
Apr 19, 2022 08:00AM Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
Apr 14, 2022 04:05PM Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
Apr 11, 2022 04:07PM Gilead Sciences (GILD) Announces FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
Apr 11, 2022 04:07PM FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
Apr 1, 2022 06:01PM Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
Mar 28, 2022 11:00AM Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere
Mar 7, 2022 08:31AM Gilead Sciences (GILD) Reports Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival
Mar 7, 2022 08:30AM Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
Mar 1, 2022 08:33AM Gilead Sciences (GILD) Receives CRL from FDA for Investigational Lenacapavir Due to Vial Compatability Issues
Mar 1, 2022 08:30AM Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues
Feb 16, 2022 01:58PM Gilead Sciences (GILD) Announces New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
Feb 16, 2022 01:55PM New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
Feb 11, 2022 05:16PM Gilead Sciences (GILD) to Present New Phase 2/3 Interim Data of Veklury in Pediatric Patients With COVID-19 Presented at CROI 2022
Feb 11, 2022 05:15PM Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
Feb 11, 2022 05:00PM Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
Feb 11, 2022 08:01AM Gilead Sciences (GILD) Announces Veklury Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
Feb 11, 2022 08:01AM Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
Feb 8, 2022 08:31AM Gilead Sciences (GILD) to Present Latest Antiviral Research and Development Data at CROI
Feb 8, 2022 08:30AM Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
Feb 3, 2022 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Feb 1, 2022 04:10PM Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
Jan 31, 2022 09:00AM Gilead Sciences (GILD) Announces U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
Jan 31, 2022 09:00AM U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
Jan 26, 2022 05:47AM Gilead Sciences (GILD) Announces FDA Clinical Hold on Studies Evaluating Magrolimab in Combination With Azacitidine
Jan 25, 2022 06:52PM Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
Jan 24, 2022 05:55AM Gilead Sciences (GILD) Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19
Jan 21, 2022 06:24PM FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
Jan 18, 2022 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
Jan 10, 2022 08:31AM Gilead Sciences (GILD) Enters Clinical Collaboration with Merck (MRK) to Evaluate Trodelvy in Combination With KEYTRUDA
Jan 10, 2022 08:30AM Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
Dec 22, 2021 05:17PM Gilead Sciences (GILD) Announces NEJM Publication of Data Demonstrating Veklury (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
Dec 22, 2021 05:08PM Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
Dec 22, 2021 05:39AM Gilead Sciences (GILD) Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
Dec 21, 2021 07:12PM Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
Dec 21, 2021 04:35PM Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-stage Programs and New Research Collaboration
Dec 21, 2021 04:35PM Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
Dec 21, 2021 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 21, 2021 05:09AM Gilead Sciences (GILD) Granted Expanded Indication for Veklury in Europe for Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Dec 21, 2021 04:00AM European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Dec 16, 2021 06:00PM Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
Dec 13, 2021 02:49PM Gilead Sciences (GILD) Announces Yescarta ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
View More Recent Stories View Older Stories